Table IV.
Haplotype analysis of MTHFR, TS and RFC1 genotypes and colorectal cancer risk.
| Haplotypes | Controls (2n=1028) | Cases (2n=954) | OR (95% CI) | P-valuea |
|---|---|---|---|---|
| MTHFR 677/1298 | ||||
| C-A | 452 (44.0) | 409 (42.9) | 0.956 (0.801–1.142) | 0.650 |
| C-C | 157 (15.3) | 157 (16.5) | 1.093 (0.859–1.391) | 0.498 |
| T-A | 419 (40.8) | 388 (40.7) | 0.996 (0.833–1.192) | 1.000 |
| TSER/TS 1494 | ||||
| 3R-0bp | 660 (64.2) | 620 (65.0) | 1.035 (0.861–1.245) | 0.742 |
| 3R-6bp | 201 (19.6) | 160 (16.8) | 0.829 (0.659–1.043) | 0.116 |
| 2R-0bp | 55 (5.4) | 63 (6.6) | 1.251 (0.861–1.816) | 0.255 |
| 2R-6bp | 112 (10.9) | 111 (11.6) | 1.077 (0.815–1.423) | 0.619 |
| RFC1 −43/80/696 | ||||
| T-G-C | 429 (41.7) | 392 (41.1) | 0.974 (0.814–1.165) | 0.784 |
| T-G-T | 9 (0.9) | 2 (0.2) | 0.238 (0.051–1.104) | 0.067 |
| T-A-C | 35 (3.4) | 28 (2.9) | 0.858 (0.518–1.422) | 0.609 |
| T-A-T | 9 (0.9) | 1 (0.1) | 0.119 (0.015–0.940) | 0.022 |
| C-G-C | 6 (0.6) | 10 (1.0) | 1.804 (0.653–4.985) | 0.317 |
| C-G-T | 4 (0.4) | 5 (0.5) | 1.349 (0.361–5.039) | 0.746 |
| C-A-C | 12 (1.2) | 9 (0.9) | 0.806 (0.338–1.923) | 0.667 |
| C-A-T | 524 (51.0) | 507 (53.1) | 1.091 (0.914–1.301) | 0.345 |
a
Models adjusted for age, gender, hypertension and diabetes mellitus status. MTHFR, methylenetetrahydrofolate reductase; TS, thymidylate synthase; TSER, TS enhancer region; RFC1, reduced folate carrier 1; OR, odds ratio; CI, confidence interval.